<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00507</drugbank-id>
  <drugbank-id>APRD00558</drugbank-id>
  <name>Nitazoxanide</name>
  <description>Nitazoxanide belongs to the class of drugs known as _thiazolides_.  Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths [A31976].  Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses [A31977].</description>
  <cas-number>55981-09-4</cas-number>
  <unii>SOA12P041N</unii>
  <average-mass>307.282</average-mass>
  <monoisotopic-mass>307.026291103</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
    <group>vet_approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A31973</ref-id>
        <pubmed-id>17722965</pubmed-id>
        <citation>Anderson VR, Curran MP: Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs. 2007;67(13):1947-67.</citation>
      </article>
      <article>
        <ref-id>A31976</ref-id>
        <pubmed-id>28748751</pubmed-id>
        <citation>Shakya A, Bhat HR, Ghosh SK: Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent. Curr Drug Discov Technol. 2017 Jul 27. pii: CDDT-EPUB-85034. doi: 10.2174/1570163814666170727130003.</citation>
      </article>
      <article>
        <ref-id>A31977</ref-id>
        <pubmed-id>25108173</pubmed-id>
        <citation>Rossignol JF: Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014 Oct;110:94-103. doi: 10.1016/j.antiviral.2014.07.014. Epub 2014 Aug 7.</citation>
      </article>
      <article>
        <ref-id>A31980</ref-id>
        <pubmed-id>16495369</pubmed-id>
        <citation>Balamurugan K, Said HM: Role of reduced folate carrier in intestinal folate uptake. Am J Physiol Cell Physiol. 2006 Jul;291(1):C189-93. doi: 10.1152/ajpcell.00594.2005. Epub 2006 Feb 22.</citation>
      </article>
      <article>
        <ref-id>A31981</ref-id>
        <pubmed-id>10984012</pubmed-id>
        <citation>Broekhuysen J, Stockis A, Lins RL, De Graeve J, Rossignol JF: Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther. 2000 Aug;38(8):387-94.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L1416</ref-id>
        <title>Nitazoxanide, Pub Chemistry</title>
        <url>https://pubchem.ncbi.nlm.nih.gov/compound/nitazoxanide#section=Top</url>
      </link>
      <link>
        <ref-id>L1417</ref-id>
        <title>EPA Chemistry Dashboard: Nitazoxanide</title>
        <url>https://comptox.epa.gov/dashboard/dsstoxdb/results?search=DTXSID5033757</url>
      </link>
      <link>
        <ref-id>L1422</ref-id>
        <title>Nitazoxanide: A New Thiazolide Antiparasitic Agent</title>
        <url>https://academic.oup.com/cid/article/40/8/1173/320667</url>
      </link>
      <link>
        <ref-id>L1424</ref-id>
        <title>Validated and optimized high-performance liquid chromatographic determination of tizoxanide, the main active metabolite of nitazoxanide in human urine, plasma and breast milk.</title>
        <url>https://watermark.silverchair.com/bms041.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAa8wggGrBgkqhkiG9w0BBwagggGcMIIBmAIBADCCAZEGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM-kpbjlKq5U2lFyDhAgEQgIIBYtw6PzXSgZ5bAcaADgK2chDdauq8S51YHhYRw2Y7CIqmEeNFeLDH-rPr1iU638KpXjSSSF4fxBrEqou8j3cmjinfNQE6HzzUfT1TW-mw2FG6HRriDDfPiAtqmYjqfHnj1uoWLgg9akVMmPkY9wzidxGUnBnkVUSeRFt2OCyUmPnB4jgKL-rn-0xMBo-jQtYEFjbZQe4yDLXsCVGzj_gOvGh6p_jYdqHBmqiSC77yOgylIcZ_OGn_RkHOnUNM66W0MIjnQb4mWYa_hRTYffMU2OX2oYVkrmOUkkDEmxeF2J3mL-xz3SKmGZ0JtwyBc_bkblRXVNt8ci9BESlTsIvnQlFY6ZP0eF21RF3IRwxZp4T5D6yZOUR9o9FLP51YoOiXvzNra-NL7gonkbC0zM32XUNXL8d2d6IB0gcGl81HVTjSjNJJ-HJKM4eI-ZUNNFu4vIVwlNA7WetsoU8aZsrzZ6w4zg</url>
      </link>
      <link>
        <ref-id>L1425</ref-id>
        <title>Pharmacology review, Nitazoxanide</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-497_Alinia_Pharmr_P1.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of diarrhea in adults and children caused by the protozoa &lt;i&gt;Giardia lamblia&lt;/i&gt;,  and for the treatment of diarrhea in children caused by the protozoan,  &lt;i&gt;Cryptosporidium parvum&lt;/i&gt; [FDA label].&#13;
&#13;
Nitazoxanide has not been shown to be superior to placebo medication for the management of diarrhea caused by Cryptosporidium parvum in patients with HIV/immunodeficiency [FDA label, A31973, A31976]. </indication>
  <pharmacodynamics>The general effect of this medication is the prevention of microbe activity through disruption of important energy pathways for survival and proliferation [FDA label, A31976].  Nitazoxanide exhibits antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction, an essential reaction need for anaerobic energy metabolism of various microorganisms.  Sporozoites of Cryptosporidium parvum and trophozoites of Giardia lamblia are therefore inhibited, relieving symptoms of diahrrea [L1425]. Interference with the PFOR enzyme-dependent electron transfer reaction may only be one of the many pathways by which nitazoxanide exhibits antiprotozoal activity [FDA label, A31973, L1425]. </pharmacodynamics>
  <mechanism-of-action>The most widely accepted mechanism of NTZ is believed to be the disruption of the energy metabolism in anaerobic microbes by inhibition of the pyruvate: ferredoxin/flavodoxin oxidoreductase (PFOR) cycle [A31981]. In parasitic-protozoa, Nitazoxanide also induces lesions in the cell membranes and depolarizes the mitochondrial membrane while inhibiting quinone oxidoreductase NQO1, nitroreductase-1 and protein disulphide isomerase enzymes. In addition, this drug also inhibits the glutathione-S-transferase (a major detoxifying enzyme) and modulates the Avr-14 gene, encoding for the alpha-type subunit of glutamate-gated chloride ion channel present in nematodes. Aside from its well understood non-competitive inhibition of the PFOR in anaerobic bacteria, NTZ also demonstrates various other antibacterial mechanisms. It inhibits pyruvate dehydrogenase in E Coli, disrupts the membrane potential and pH homeostasis in the Mycobacterium tuberculosis, suppresses the chaperone/usher (CU) pathway of the gram-negative bacteria,  and stimulates host macrophage autophagy in tuberculosis patients [A31976]. NTZ also suppresses viral replication by inhibiting the maturation of the viral hemagglutinin and the viral transcription factor immediate early 2 (IE2) as well as by activating the eukaryotic translation initiation factor 2α (an antiviral intracellular protein). Lastly, NTZ exhibits an inhibitory effect on tumor cell progression by altering drug detoxification (glutathione-S-transferase P1), unfolded protein response, autophagy, anti-cytokines activity, and c-Myc inhibition [A31976].</mechanism-of-action>
  <toxicity>Data on nitazoxanide overdosage is not available [FDA label]. In studies in rodents and dogs, the oral LD50 was higher than 10,000 mg/kg. One-time oral doses of up to 4000 mg nitazoxanide have been given to healthy adult volunteers without severe adverse effects. Gastric lavage may be appropriate soon after oral administration if overdose occurs. Supportive and symptomatic treatment should also be administered [FDA label].&#13;
&#13;
&#13;
According to previous studies [FDA label], less than 1% of the patients age 12 years and older participating in clinical trials with NTZ suffered from the following adverse effects:&#13;
Systemic: asthenia, fever, pain, allergic reaction, pelvic pain, back pain, chills, fever, flu-like syndrome.&#13;
Central Nervous System: dizziness, somnolence, insomnia, tremor, hypesthesia.&#13;
Gastrointestinal System: vomiting, dyspepsia, anorexia, flatulence, constipation, dry mouth, thirst. &#13;
Urogenital System: discolored urine, dysuria, amenorrhea, metrorrhagia, kidney pain, edema labia. &#13;
Metabolic &amp; Nutrition: increased SGPT.&#13;
Hemic &amp; Lymphatic Systems: anemia, leukocytosis.&#13;
Skin: rash, pruritus.&#13;
Special Senses: eye discoloration, ear ache.&#13;
Respiratory System: epistaxis, lung disease, pharyngitis.&#13;
Cardiovascular System: tachycardia, syncope, hypertension.&#13;
Muscular System: myalgia, leg cramps, spontaneous bone fracture.&#13;
&#13;
  </toxicity>
  <metabolism>The active metabolite of this drug is tizoxanide (desacetyl-nitazoxanide). The initial reaction in the metabolic pathway of Nitazoxanide is hydrolysis to tizoxanide,  followed by conjugation, primarily by glucuronidation to tizoxanide glucuronide.&#13;
&#13;
The oral suspension bioavailability of this drug is not equivalent to that of the oral tablets. Compared to the to the tablet, the bioavailability of the suspension was 70% [FDA label].&#13;
&#13;
When administered with food, the AUCt of tizoxanide and tizoxanide glucuronide in plasma is increased to almost two-fold and the maximum concentration is increased by almost 50% compared to when ingested without food [FDA label].&#13;
&#13;
When the oral suspension was ingested with food, the AUC of tizoxanide and tizoxanide glucuronide increased by approximately 50% and the Cmax increased by less than 10% [FDA label].</metabolism>
  <absorption>The relative bioavailability of the suspension compared to the tablet was 70%. When administered with food the AUC and C&lt;sub&gt;max&lt;/sub&gt; increased by two-fold and 50%, respectively, for the tablet and 45 to 50% and &amp;le; 10%, respectively, for the oral suspension [FDA label].</absorption>
  <half-life>7.3h [L1422]</half-life>
  <protein-binding>Very High (greater than 99%), bound to proteins in the plasma [FDA label, A31981].</protein-binding>
  <route-of-elimination>Tizoxanide is excreted in the urine, bile and feces, and tizoxanide glucuronide is excreted in urine and bile. Approximately 2/3 of the oral dose of nitazoxanide is excreted in the faeces and 1/3 in the urine [FDA label, A31981].</route-of-elimination>
  <volume-of-distribution/>
  <clearance>Nitazoxanide is cleared in the urine and feces. The metabolite, tizoxanide, is also found in the urine, plasma, and breastmilk [L1424].  The drug is not found unchanged in the urine [L1424].</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as acylsalicylamides. These are o-acylated derivatives of salicylamide.</description>
    <direct-parent>Acylsalicylamides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Benzoic acids and derivatives</subclass>
    <alternative-parent>2,5-disubstituted thiazoles</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzamides</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Nitroaromatic compounds</alternative-parent>
    <alternative-parent>Nitrothiazoles</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organic oxoazanium compounds</alternative-parent>
    <alternative-parent>Organic zwitterions</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenol esters</alternative-parent>
    <alternative-parent>Phenoxy compounds</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <substituent>2,5-disubstituted 1,3-thiazole</substituent>
    <substituent>Acylsalicylamide</substituent>
    <substituent>Allyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Aromatic heteromonocyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Benzamide</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>C-nitro compound</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Nitroaromatic compound</substituent>
    <substituent>Nitrothiazole</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitro compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxoazanium</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic zwitterion</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenol ester</substituent>
    <substituent>Phenoxy compound</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Thiazole</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="german" coder="inn">Nitaxozanid</synonym>
    <synonym language="french" coder="inn">Nitaxozanide</synonym>
    <synonym language="spanish" coder="inn">Nitazoxanida</synonym>
    <synonym language="english" coder="inn/usan">Nitazoxanide</synonym>
    <synonym language="latin" coder="inn">Nitazoxanidum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Alinia</name>
      <labeller>Avera McKennan Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>69189-0243</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-26</started-marketing-on>
      <ended-marketing-on>2018-06-18</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>500 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021497</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alinia</name>
      <labeller>Lupin Pharma</labeller>
      <ndc-id/>
      <ndc-product-code>27437-106</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-10-09</started-marketing-on>
      <ended-marketing-on>2018-07-31</ended-marketing-on>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>100 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA021498</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alinia</name>
      <labeller>Romark Laboratories, L.C.</labeller>
      <ndc-id/>
      <ndc-product-code>67546-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-07-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>500 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021497</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Alinia</name>
      <labeller>Romark Laboratories, L.C.</labeller>
      <ndc-id/>
      <ndc-product-code>67546-212</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for suspension</dosage-form>
      <strength>100 mg/5mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA021498</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Alpex Nizox</name>
      <company>Alpex Pharmaceutical</company>
    </international-brand>
    <international-brand>
      <name>ANNITA</name>
      <company>Alpex Pharmaceutical</company>
    </international-brand>
    <international-brand>
      <name>Azoxanid</name>
      <company>G&amp;R</company>
    </international-brand>
    <international-brand>
      <name>Celectan</name>
      <company>Farma</company>
    </international-brand>
    <international-brand>
      <name>Colufase</name>
      <company>Roemmers</company>
    </international-brand>
    <international-brand>
      <name>Coluquim</name>
      <company>Quilab</company>
    </international-brand>
    <international-brand>
      <name>Daxon</name>
      <company>Siegfried</company>
    </international-brand>
    <international-brand>
      <name>Dianide</name>
      <company>General Pharma</company>
    </international-brand>
    <international-brand>
      <name>Diar</name>
      <company>ACI</company>
    </international-brand>
    <international-brand>
      <name>Famidox</name>
      <company>Lafrancol</company>
    </international-brand>
    <international-brand>
      <name>Kaside</name>
      <company>Lafrancol</company>
    </international-brand>
    <international-brand>
      <name>Kazide</name>
      <company>Lafrancol</company>
    </international-brand>
    <international-brand>
      <name>Larvisol</name>
      <company>Armofar</company>
    </international-brand>
    <international-brand>
      <name>Lumbris</name>
      <company>Farmedic</company>
    </international-brand>
    <international-brand>
      <name>Mixel</name>
      <company>California</company>
    </international-brand>
    <international-brand>
      <name>Niazid</name>
      <company>Apex</company>
    </international-brand>
    <international-brand>
      <name>Nitax</name>
      <company>Delta</company>
    </international-brand>
    <international-brand>
      <name>Nitaxide</name>
      <company>Beximco</company>
    </international-brand>
    <international-brand>
      <name>Nitazet</name>
      <company>Glenmark</company>
    </international-brand>
    <international-brand>
      <name>Nitazofin</name>
      <company>Bussié</company>
    </international-brand>
    <international-brand>
      <name>Nodik</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Omniparax</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Alinia</name>
      <ingredients>Nitazoxanide</ingredients>
    </mixture>
    <mixture>
      <name>Alinia</name>
      <ingredients>Nitazoxanide</ingredients>
    </mixture>
    <mixture>
      <name>Alinia</name>
      <ingredients>Nitazoxanide</ingredients>
    </mixture>
    <mixture>
      <name>Alinia</name>
      <ingredients>Nitazoxanide</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Industriale Chimica S.R.L.</name>
      <url/>
    </packager>
    <packager>
      <name>Laboratoria Qualiphar NV SA</name>
      <url>http://www.qualiphar.com</url>
    </packager>
    <packager>
      <name>Murfreesboro Pharmaceutical Nursing Supply</name>
      <url>http://www.unitdosesupply.com</url>
    </packager>
    <packager>
      <name>Romark Pharmaceuticals</name>
      <url>http://www.romark.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Romark laboratories</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Alinia 500 mg tablet</description>
      <cost currency="USD">23.22</cost>
      <unit>tablet</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antiparasitic Agents</category>
      <mesh-id>D000977</mesh-id>
    </category>
    <category>
      <category>Antiparasitic Products, Insecticides and Repellents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antiprotozoals</category>
      <mesh-id>D000981</mesh-id>
    </category>
    <category>
      <category>Sulfur Compounds</category>
      <mesh-id>D013457</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Mycobacterium tuberculosis</affected-organism>
    <affected-organism>Helminthic Microorganisms</affected-organism>
    <affected-organism>Bacteria and protozoa</affected-organism>
    <affected-organism>Escherichia coli</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder, for suspension</form>
      <route>Oral</route>
      <strength>100 mg/5mL</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>500 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="P01AX11">
      <level code="P01AX">Other agents against amoebiasis and other protozoal diseases</level>
      <level code="P01A">AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES</level>
      <level code="P01">ANTIPROTOZOALS</level>
      <level code="P">ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>3v35</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00507.pdf?1265922810</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00507.pdf?1265922747</msds>
  <patents>
    <patent>
      <number>5387598</number>
      <country>United States</country>
      <approved>1995-02-07</approved>
      <expires>2012-02-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5968961</number>
      <country>United States</country>
      <approved>1999-10-19</approved>
      <expires>2017-05-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5965590</number>
      <country>United States</country>
      <approved>1999-10-12</approved>
      <expires>2017-07-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6117894</number>
      <country>United States</country>
      <approved>2000-09-12</approved>
      <expires>2017-05-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.14</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>7.55e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>nitazoxanide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>307.282</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>307.026291103</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C12H9N3O5S</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>YQNQNVDNTFHQSW-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>114.11</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>73.89</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>27.54</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>8.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-4.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>1.89e-04</value>
      <source>[L1417]</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>202 °C </value>
      <source>[L1417]</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>394</value>
      <source>[L1417]</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.63 </value>
      <source>[L1417]</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>94807</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>41684</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507813</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D02486</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>38037</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50075050</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164754874</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>NTI</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001293</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Nitazoxanide</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1401</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/alinia.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ali1659.shtml</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/nitazoxanide.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00507</drugbank-id>
        <name>Nitazoxanide</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01012</drugbank-id>
        <name>Desacetyl-nitazoxanide</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0000457</drugbank-id>
          <name>Ectonucleotide pyrophosphatase/phosphodiesterase family member 1</name>
          <uniprot-id>P22413</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB00507</drugbank-id>
        <name>Nitazoxanide</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01013</drugbank-id>
        <name>Tizoxanide glucuronide</name>
      </right-element>
      <enzymes/>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0002674</id>
      <name>Pyruvate-flavodoxin oxidoreductase</name>
      <organism>Desulfovibrio africanus</organism>
      <actions>
        <action>antagonist</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15426</ref-id>
            <pubmed-id>17158936</pubmed-id>
            <citation>Hoffman PS, Sisson G, Croxen MA, Welch K, Harman WD, Cremades N, Morash MG: Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob Agents Chemother. 2007 Mar;51(3):868-76. Epub 2006 Dec 11.</citation>
          </article>
          <article>
            <ref-id>A15427</ref-id>
            <pubmed-id>20488706</pubmed-id>
            <citation>Ballard TE, Wang X, Olekhnovich I, Koerner T, Seymour C, Hoffman PS, Macdonald TL: Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3537-9. doi: 10.1016/j.bmcl.2010.04.126. Epub 2010 May 18.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P94692" source="Swiss-Prot">
        <name>Pyruvate synthase</name>
        <general-function>Thiamine pyrophosphate binding</general-function>
        <specific-function>Catalyzes the ferredoxin-dependent oxidative decarboxylation of pyruvate. Required for the transfer of electrons from pyruvate to ferredoxin (PubMed:9294422, PubMed:7612653). Ferredoxin I and ferredoxin II, which are single 4Fe-4S cluster ferredoxins are the most effective electron carriers of POR (PubMed:7612653).</specific-function>
        <gene-name>por</gene-name>
        <locus/>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.81</theoretical-pi>
        <molecular-weight>133679.405</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="873">Desulfovibrio africanus</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Y09702</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P94692</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>POR_DESAF</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.2.7.1</synonym>
          <synonym>POR</synonym>
          <synonym>Pyruvate-ferredoxin oxidoreductase.</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019316|Pyruvate synthase
MGKKMMTTDGNTATAHVAYAMSEVAAIYPITPSSTMGEEADDWAAQGRKNIFGQTLTIRE
MQSEAGAAGAVHGALAAGALTTTFTASQGLLLMIPNMYKISGELLPGVFHVTARAIAAHA
LSIFGDHQDIYAARQTGFAMLASSSVQEAHDMALVAHLAAIESNVPFMHFFDGFRTSHEI
QKIEVLDYADMASLVNQKALAEFRAKSMNPEHPHVRGTAQNPDIYFQGREAANPYYLKVP
GIVAEYMQKVASLTGRSYKLFDYVGAPDAERVIVSMGSSCETIEEVINHLAAKGEKIGLI
KVRLYRPFVSEAFFAALPASAKVITVLDRTKEPGAPGDPLYLDVCSAFVERGEAMPKILA
GRYGLGSKEFSPAMVKSVYDNMSGAKKNHFTVGIEDDVTGTSLPVDNAFADTTPKGTIQC
QFWGLGADGTVGANKQAIKIIGDNTDLFAQGYFSYDSKKSGGITISHLRFGEKPIQSTYL
VNRADYVACHNPAYVGIYDILEGIKDGGTFVLNSPWSSLEDMDKHLPSGIKRTIANKKLK
FYNIDAVKIATDVGLGGRINMIMQTAFFKLAGVLPFEKAVDLLKKSIHKAYGKKGEKIVK
MNTDAVDQAVTSLQEFKYPDSWKDAPAETKAEPMTNEFFKNVVKPILTQQGDKLPVSAFE
ADGRFPLGTSQFEKRGVAINVPQWVPENCIQCNQCAFVCPHSAILPVLAKEEELVGAPAN
FTALEAKGKELKGYKFRIQINTLDCMGCGNCADICPPKEKALVMQPLDTQRDAQVPNLEY
AARIPVKSEVLPRDSLKGSQFQEPLMEFSGACSGCGETPYVRVITQLFGERMFIANATGC
SSIWGASAPSMPYKTNRLGQGPAWGNSLFEDAAEYGFGMNMSMFARRTHLADLAAKALES
DASGDVKEALQGWLAGKNDPIKSKEYGDKLKKLLAGQKDGLLGQIAAMSDLYTKKSVWIF
GGDGWAYDIGYGGLDHVLASGEDVNVFVMDTEVYSNTGGQSSKATPTGAVAKFAAAGKRT
GKKDLARMVMTYGYVYVATVSMGYSKQQFLKVLKEAESFPGPSLVIAYATCINQGLRKGM
GKSQDVMNTAVKSGYWPLFRYDPRLAAQGKNPFQLDSKAPDGSVEEFLMAQNRFAVLDRS
FPEDAKRLRAQVAHELDVRFKELEHMAATNIFESFAPAGGKADGSVDFGEGAEFCTRDDT
PMMARPDSGEACDQNRAGTSEQQGDLSKRTKK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0005243|3699 bp
ATGGGAAAGAAAATGATGACGACTGATGGCAATACAGCGACAGCGCACGTGGCGTATGCC
ATGAGCGAAGTCGCCGCCATCTACCCCATCACCCCTTCCTCGACCATGGGCGAGGAGGCT
GACGACTGGGCGGCGCAAGGACGCAAGAACATCTTTGGCCAGACCCTGACCATACGCGAA
ATGCAGTCCGAGGCCGGCGCCGCCGGCGCGGTGCACGGGGCCCTGGCGGCCGGCGCCCTG
ACCACGACCTTCACGGCGTCGCAGGGTCTGCTGCTGATGATCCCCAACATGTACAAGATC
TCCGGCGAACTTCTGCCCGGCGTGTTCCACGTCACCGCCCGCGCCATCGCCGCGCACGCC
CTGTCCATCTTCGGTGACCACCAGGATATCTACGCCGCGCGCCAGACAGGCTTCGCCATG
CTCGCCTCCAGCTCGGTGCAGGAGGCCCACGACATGGCCCTGGTGGCCCACTTGGCGGCC
ATCGAGTCCAACGTGCCGTTCATGCACTTCTTCGACGGATTCCGCACCTCGCACGAAATC
CAGAAGATCGAGGTCCTGGACTACGCGGACATGGCCTCGCTGGTGAACCAGAAGGCCCTG
GCGGAATTCCGCGCCAAGTCCATGAACCCCGAGCACCCCCACGTGCGCGGCACGGCCCAG
AACCCCGACATCTACTTCCAGGGTCGCGAGGCAGCCAACCCCTACTACCTCAAGGTGCCC
GGCATCGTTGCCGAGTACATGCAGAAGGTCGCCTCCCTCACGGGCCGCAGCTACAAGCTC
TTTGACTACGTGGGTGCTCCCGACGCCGAGCGCGTCATCGTGTCCATGGGCTCCTCGTGC
GAGACCATCGAGGAGGTCATCAACCACCTCGCGGCCAAGGGCGAAAAGATCGGCCTGATC
AAGGTCCGCCTGTACAGGCCCTTCGTAAGCGAGGCCTTCTTCGCTGCTCTGCCCGCTTCG
GCCAAGGTCATCACGGTCCTCGACCGCACCAAGGAACCCGGCGCGCCCGGCGATCCGCTC
TACCTCGACGTGTGCTCGGCCTTCGTGGAGCGCGGCGAAGCCATGCCCAAGATCCTGGCC
GGCCGCTACGGCCTGGGTTCCAAGGAATTCAGCCCGGCCATGGTCAAGTCCGTGTACGAC
AACATGTCCGGCGCTAAGAAGAACCACTTCACCGTGGGCATCGAAGACGACGTGACCGGC
ACTTCGCTGCCGGTGGACAACGCCTTCGCCGACACCACGCCCAAGGGCACCATCCAGTGC
CAGTTCTGGGGCCTCGGCGCCGACGGCACTGTGGGCGCCAACAAGCAGGCCATCAAGATC
ATCGGCGACAACACGGACCTGTTTGCCCAGGGTTACTTCTCCTACGACTCCAAGAAATCG
GGCGGCATCACCATCTCGCACCTGCGCTTCGGCGAGAAGCCCATCCAGTCCACCTACCTG
GTCAACAGGGCCGACTATGTCGCCTGTCACAACCCGGCCTACGTGGGCATATACGACATC
CTCGAAGGCATCAAGGATGGCGGAACCTTCGTGCTCAACTCGCCTTGGAGCAGCCTCGAG
GACATGGACAAGCACCTGCCCTCCGGCATCAAGCGCACCATCGCGAACAAGAAGCTCAAG
TTCTACAACATCGACGCGGTGAAAATCGCCACCGATGTGGGACTGGGCGGCCGCATCAAC
ATGATCATGCAGACGGCCTTCTTCAAGCTGGCCGGAGTGCTGCCCTTCGAAAAGGCCGTG
GATCTGCTCAAGAAGTCCATCCACAAGGCCTACGGCAAAAAGGGCGAGAAGATCGTCAAG
ATGAACACCGACGCCGTGGACCAGGCCGTCACCTCCCTGCAGGAATTCAAGTATCCGGAT
TCCTGGAAGGACGCTCCCGCTGAGACCAAGGCCGAGCCCATGACGAACGAGTTCTTCAAG
AACGTCGTCAAGCCCATCCTGACCCAGCAGGGCGACAAGCTGCCGGTGAGCGCCTTCGAG
GCCGACGGCCGTTTCCCCCTCGGCACCAGCCAGTTCGAGAAGCGCGGCGTGGCCATCAAC
GTGCCGCAGTGGGTCCCCGAGAACTGCATCCAGTGCAACCAGTGCGCCTTCGTCTGTCCG
CACAGCGCCATCCTGCCCGTGCTGGCCAAGGAAGAGGAGTTGGTCGGCGCGCCGGCGAAC
TTCACGGCCCTGGAAGCCAAGGGCAAGGAGCTCAAGGGCTACAAGTTCCGCATCCAGATC
AACACCCTGGACTGCATGGGCTGCGGCAACTGCGCCGACATCTGTCCGCCCAAGGAAAAG
GCTCTGGTCATGCAGCCCCTGGATACCCAGCGCGACGCGCAGGTGCCCAACCTGGAGTAC
GCAGCGCGCATCCCGGTCAAATCCGAGGTGCTGCCGCGCGACTCGCTCAAGGGCAGCCAG
TTCCAGGAGCCTCTCATGGAATTCTCGGGCGCCTGCTCGGGCTGCGGCGAGACGCCCTAC
GTGCGCGTCATCACCCAGCTCTTCGGCGAGCGCATGTTCATTGCCAACGCCACGGGTTGC
TCGTCCATCTGGGGCGCGTCGGCTCCTTCCATGCCTTACAAGACCAACCGCCTCGGACAA
GGCCCGGCCTGGGGTAACTCCCTGTTCGAAGACGCGGCCGAATACGGCTTCGGCATGAAC
ATGTCCATGTTCGCCCGCCGCACGCATTTGGCCGATCTTGCCGCCAAGGCCCTGGAGAGC
GATGCCTCCGGCGATGTCAAGGAAGCCCTGCAGGGCTGGCTTGCCGGCAAGAACGATCCC
ATCAAGTCCAAGGAATACGGCGACAAGCTCAAGAAGCTGCTGGCTGGTCAGAAGGATGGT
CTGCTCGGACAGATCGCCGCCATGTCCGACCTGTACACCAAGAAGAGCGTGTGGATCTTC
GGTGGCGACGGCTGGGCCTACGACATCGGTTACGGCGGCCTGGACCATGTGCTCGCCTCG
GGCGAGGACGTGAACGTCTTCGTCATGGATACCGAGGTCTACTCCAACACCGGCGGCCAG
TCCTCCAAGGCAACGCCCACGGGCGCCGTGGCCAAGTTCGCGGCGGCCGGCAAGCGTACC
GGCAAGAAGGACCTGGCGCGCATGGTCATGACCTACGGCTACGTCTACGTGGCTACGGTC
TCCATGGGTTACAGCAAGCAGCAGTTCCTCAAGGTGCTCAAGGAAGCCGAAAGCTTCCCC
GGCCCCTCGCTGGTCATCGCCTATGCTACCTGCATCAACCAGGGTCTGCGCAAGGGCATG
GGCAAGAGCCAGGACGTCATGAACACCGCGGTCAAGTCCGGTTACTGGCCGCTGTTCCGC
TACGATCCGCGCTTGGCCGCCCAGGGCAAGAACCCCTTCCAGCTCGACTCCAAGGCTCCT
GACGGTTCCGTCGAGGAGTTCCTGATGGCCCAGAACCGCTTCGCCGTCCTCGATCGGTCC
TTCCCCGAGGACGCCAAGAGACTGCGCGCCCAGGTCGCTCACGAATTGGACGTGCGTTTC
AAGGAGTTGGAGCACATGGCCGCCACGAACATCTTCGAGTCCTTCGCGCCAGCGGGCGGC
AAGGCCGATGGTTCGGTGGATTTCGGCGAAGGTGCGGAGTTCTGCACGCGCGACGATACT
CCCATGATGGCCCGACCTGATTCCGGTGAGGCCTGCGACCAGAACCGCGCTGGCACGAGC
GAACAGCAGGGAGACCTCAGCAAGCGGACGAAGAAGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02775</identifier>
            <name>TPP_enzyme_C</name>
          </pfam>
          <pfam>
            <identifier>PF01558</identifier>
            <name>POR</name>
          </pfam>
          <pfam>
            <identifier>PF01855</identifier>
            <name>POR_N</name>
          </pfam>
          <pfam>
            <identifier>PF10371</identifier>
            <name>EKR</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>4 iron, 4 sulfur cluster binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyruvate synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thiamine pyrophosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>electron transport chain</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="2">
      <id>BE0002674</id>
      <name>Pyruvate-flavodoxin oxidoreductase</name>
      <organism>Desulfovibrio africanus</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A31973</ref-id>
            <pubmed-id>17722965</pubmed-id>
            <citation>Anderson VR, Curran MP: Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs. 2007;67(13):1947-67.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P94692" source="Swiss-Prot">
        <name>Pyruvate synthase</name>
        <general-function>Thiamine pyrophosphate binding</general-function>
        <specific-function>Catalyzes the ferredoxin-dependent oxidative decarboxylation of pyruvate. Required for the transfer of electrons from pyruvate to ferredoxin (PubMed:9294422, PubMed:7612653). Ferredoxin I and ferredoxin II, which are single 4Fe-4S cluster ferredoxins are the most effective electron carriers of POR (PubMed:7612653).</specific-function>
        <gene-name>por</gene-name>
        <locus/>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.81</theoretical-pi>
        <molecular-weight>133679.405</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="873">Desulfovibrio africanus</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Y09702</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P94692</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>POR_DESAF</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.2.7.1</synonym>
          <synonym>POR</synonym>
          <synonym>Pyruvate-ferredoxin oxidoreductase.</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019316|Pyruvate synthase
MGKKMMTTDGNTATAHVAYAMSEVAAIYPITPSSTMGEEADDWAAQGRKNIFGQTLTIRE
MQSEAGAAGAVHGALAAGALTTTFTASQGLLLMIPNMYKISGELLPGVFHVTARAIAAHA
LSIFGDHQDIYAARQTGFAMLASSSVQEAHDMALVAHLAAIESNVPFMHFFDGFRTSHEI
QKIEVLDYADMASLVNQKALAEFRAKSMNPEHPHVRGTAQNPDIYFQGREAANPYYLKVP
GIVAEYMQKVASLTGRSYKLFDYVGAPDAERVIVSMGSSCETIEEVINHLAAKGEKIGLI
KVRLYRPFVSEAFFAALPASAKVITVLDRTKEPGAPGDPLYLDVCSAFVERGEAMPKILA
GRYGLGSKEFSPAMVKSVYDNMSGAKKNHFTVGIEDDVTGTSLPVDNAFADTTPKGTIQC
QFWGLGADGTVGANKQAIKIIGDNTDLFAQGYFSYDSKKSGGITISHLRFGEKPIQSTYL
VNRADYVACHNPAYVGIYDILEGIKDGGTFVLNSPWSSLEDMDKHLPSGIKRTIANKKLK
FYNIDAVKIATDVGLGGRINMIMQTAFFKLAGVLPFEKAVDLLKKSIHKAYGKKGEKIVK
MNTDAVDQAVTSLQEFKYPDSWKDAPAETKAEPMTNEFFKNVVKPILTQQGDKLPVSAFE
ADGRFPLGTSQFEKRGVAINVPQWVPENCIQCNQCAFVCPHSAILPVLAKEEELVGAPAN
FTALEAKGKELKGYKFRIQINTLDCMGCGNCADICPPKEKALVMQPLDTQRDAQVPNLEY
AARIPVKSEVLPRDSLKGSQFQEPLMEFSGACSGCGETPYVRVITQLFGERMFIANATGC
SSIWGASAPSMPYKTNRLGQGPAWGNSLFEDAAEYGFGMNMSMFARRTHLADLAAKALES
DASGDVKEALQGWLAGKNDPIKSKEYGDKLKKLLAGQKDGLLGQIAAMSDLYTKKSVWIF
GGDGWAYDIGYGGLDHVLASGEDVNVFVMDTEVYSNTGGQSSKATPTGAVAKFAAAGKRT
GKKDLARMVMTYGYVYVATVSMGYSKQQFLKVLKEAESFPGPSLVIAYATCINQGLRKGM
GKSQDVMNTAVKSGYWPLFRYDPRLAAQGKNPFQLDSKAPDGSVEEFLMAQNRFAVLDRS
FPEDAKRLRAQVAHELDVRFKELEHMAATNIFESFAPAGGKADGSVDFGEGAEFCTRDDT
PMMARPDSGEACDQNRAGTSEQQGDLSKRTKK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0005243|3699 bp
ATGGGAAAGAAAATGATGACGACTGATGGCAATACAGCGACAGCGCACGTGGCGTATGCC
ATGAGCGAAGTCGCCGCCATCTACCCCATCACCCCTTCCTCGACCATGGGCGAGGAGGCT
GACGACTGGGCGGCGCAAGGACGCAAGAACATCTTTGGCCAGACCCTGACCATACGCGAA
ATGCAGTCCGAGGCCGGCGCCGCCGGCGCGGTGCACGGGGCCCTGGCGGCCGGCGCCCTG
ACCACGACCTTCACGGCGTCGCAGGGTCTGCTGCTGATGATCCCCAACATGTACAAGATC
TCCGGCGAACTTCTGCCCGGCGTGTTCCACGTCACCGCCCGCGCCATCGCCGCGCACGCC
CTGTCCATCTTCGGTGACCACCAGGATATCTACGCCGCGCGCCAGACAGGCTTCGCCATG
CTCGCCTCCAGCTCGGTGCAGGAGGCCCACGACATGGCCCTGGTGGCCCACTTGGCGGCC
ATCGAGTCCAACGTGCCGTTCATGCACTTCTTCGACGGATTCCGCACCTCGCACGAAATC
CAGAAGATCGAGGTCCTGGACTACGCGGACATGGCCTCGCTGGTGAACCAGAAGGCCCTG
GCGGAATTCCGCGCCAAGTCCATGAACCCCGAGCACCCCCACGTGCGCGGCACGGCCCAG
AACCCCGACATCTACTTCCAGGGTCGCGAGGCAGCCAACCCCTACTACCTCAAGGTGCCC
GGCATCGTTGCCGAGTACATGCAGAAGGTCGCCTCCCTCACGGGCCGCAGCTACAAGCTC
TTTGACTACGTGGGTGCTCCCGACGCCGAGCGCGTCATCGTGTCCATGGGCTCCTCGTGC
GAGACCATCGAGGAGGTCATCAACCACCTCGCGGCCAAGGGCGAAAAGATCGGCCTGATC
AAGGTCCGCCTGTACAGGCCCTTCGTAAGCGAGGCCTTCTTCGCTGCTCTGCCCGCTTCG
GCCAAGGTCATCACGGTCCTCGACCGCACCAAGGAACCCGGCGCGCCCGGCGATCCGCTC
TACCTCGACGTGTGCTCGGCCTTCGTGGAGCGCGGCGAAGCCATGCCCAAGATCCTGGCC
GGCCGCTACGGCCTGGGTTCCAAGGAATTCAGCCCGGCCATGGTCAAGTCCGTGTACGAC
AACATGTCCGGCGCTAAGAAGAACCACTTCACCGTGGGCATCGAAGACGACGTGACCGGC
ACTTCGCTGCCGGTGGACAACGCCTTCGCCGACACCACGCCCAAGGGCACCATCCAGTGC
CAGTTCTGGGGCCTCGGCGCCGACGGCACTGTGGGCGCCAACAAGCAGGCCATCAAGATC
ATCGGCGACAACACGGACCTGTTTGCCCAGGGTTACTTCTCCTACGACTCCAAGAAATCG
GGCGGCATCACCATCTCGCACCTGCGCTTCGGCGAGAAGCCCATCCAGTCCACCTACCTG
GTCAACAGGGCCGACTATGTCGCCTGTCACAACCCGGCCTACGTGGGCATATACGACATC
CTCGAAGGCATCAAGGATGGCGGAACCTTCGTGCTCAACTCGCCTTGGAGCAGCCTCGAG
GACATGGACAAGCACCTGCCCTCCGGCATCAAGCGCACCATCGCGAACAAGAAGCTCAAG
TTCTACAACATCGACGCGGTGAAAATCGCCACCGATGTGGGACTGGGCGGCCGCATCAAC
ATGATCATGCAGACGGCCTTCTTCAAGCTGGCCGGAGTGCTGCCCTTCGAAAAGGCCGTG
GATCTGCTCAAGAAGTCCATCCACAAGGCCTACGGCAAAAAGGGCGAGAAGATCGTCAAG
ATGAACACCGACGCCGTGGACCAGGCCGTCACCTCCCTGCAGGAATTCAAGTATCCGGAT
TCCTGGAAGGACGCTCCCGCTGAGACCAAGGCCGAGCCCATGACGAACGAGTTCTTCAAG
AACGTCGTCAAGCCCATCCTGACCCAGCAGGGCGACAAGCTGCCGGTGAGCGCCTTCGAG
GCCGACGGCCGTTTCCCCCTCGGCACCAGCCAGTTCGAGAAGCGCGGCGTGGCCATCAAC
GTGCCGCAGTGGGTCCCCGAGAACTGCATCCAGTGCAACCAGTGCGCCTTCGTCTGTCCG
CACAGCGCCATCCTGCCCGTGCTGGCCAAGGAAGAGGAGTTGGTCGGCGCGCCGGCGAAC
TTCACGGCCCTGGAAGCCAAGGGCAAGGAGCTCAAGGGCTACAAGTTCCGCATCCAGATC
AACACCCTGGACTGCATGGGCTGCGGCAACTGCGCCGACATCTGTCCGCCCAAGGAAAAG
GCTCTGGTCATGCAGCCCCTGGATACCCAGCGCGACGCGCAGGTGCCCAACCTGGAGTAC
GCAGCGCGCATCCCGGTCAAATCCGAGGTGCTGCCGCGCGACTCGCTCAAGGGCAGCCAG
TTCCAGGAGCCTCTCATGGAATTCTCGGGCGCCTGCTCGGGCTGCGGCGAGACGCCCTAC
GTGCGCGTCATCACCCAGCTCTTCGGCGAGCGCATGTTCATTGCCAACGCCACGGGTTGC
TCGTCCATCTGGGGCGCGTCGGCTCCTTCCATGCCTTACAAGACCAACCGCCTCGGACAA
GGCCCGGCCTGGGGTAACTCCCTGTTCGAAGACGCGGCCGAATACGGCTTCGGCATGAAC
ATGTCCATGTTCGCCCGCCGCACGCATTTGGCCGATCTTGCCGCCAAGGCCCTGGAGAGC
GATGCCTCCGGCGATGTCAAGGAAGCCCTGCAGGGCTGGCTTGCCGGCAAGAACGATCCC
ATCAAGTCCAAGGAATACGGCGACAAGCTCAAGAAGCTGCTGGCTGGTCAGAAGGATGGT
CTGCTCGGACAGATCGCCGCCATGTCCGACCTGTACACCAAGAAGAGCGTGTGGATCTTC
GGTGGCGACGGCTGGGCCTACGACATCGGTTACGGCGGCCTGGACCATGTGCTCGCCTCG
GGCGAGGACGTGAACGTCTTCGTCATGGATACCGAGGTCTACTCCAACACCGGCGGCCAG
TCCTCCAAGGCAACGCCCACGGGCGCCGTGGCCAAGTTCGCGGCGGCCGGCAAGCGTACC
GGCAAGAAGGACCTGGCGCGCATGGTCATGACCTACGGCTACGTCTACGTGGCTACGGTC
TCCATGGGTTACAGCAAGCAGCAGTTCCTCAAGGTGCTCAAGGAAGCCGAAAGCTTCCCC
GGCCCCTCGCTGGTCATCGCCTATGCTACCTGCATCAACCAGGGTCTGCGCAAGGGCATG
GGCAAGAGCCAGGACGTCATGAACACCGCGGTCAAGTCCGGTTACTGGCCGCTGTTCCGC
TACGATCCGCGCTTGGCCGCCCAGGGCAAGAACCCCTTCCAGCTCGACTCCAAGGCTCCT
GACGGTTCCGTCGAGGAGTTCCTGATGGCCCAGAACCGCTTCGCCGTCCTCGATCGGTCC
TTCCCCGAGGACGCCAAGAGACTGCGCGCCCAGGTCGCTCACGAATTGGACGTGCGTTTC
AAGGAGTTGGAGCACATGGCCGCCACGAACATCTTCGAGTCCTTCGCGCCAGCGGGCGGC
AAGGCCGATGGTTCGGTGGATTTCGGCGAAGGTGCGGAGTTCTGCACGCGCGACGATACT
CCCATGATGGCCCGACCTGATTCCGGTGAGGCCTGCGACCAGAACCGCGCTGGCACGAGC
GAACAGCAGGGAGACCTCAGCAAGCGGACGAAGAAGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02775</identifier>
            <name>TPP_enzyme_C</name>
          </pfam>
          <pfam>
            <identifier>PF01558</identifier>
            <name>POR</name>
          </pfam>
          <pfam>
            <identifier>PF01855</identifier>
            <name>POR_N</name>
          </pfam>
          <pfam>
            <identifier>PF10371</identifier>
            <name>EKR</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>4 iron, 4 sulfur cluster binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyruvate synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thiamine pyrophosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>electron transport chain</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers>
    <carrier position="3">
      <id>BE0004711</id>
      <name>Folate transporter 1</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A31980</ref-id>
            <pubmed-id>16495369</pubmed-id>
            <citation>Balamurugan K, Said HM: Role of reduced folate carrier in intestinal folate uptake. Am J Physiol Cell Physiol. 2006 Jul;291(1):C189-93. doi: 10.1152/ajpcell.00594.2005. Epub 2006 Feb 22.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P41440" source="Swiss-Prot">
        <name>Folate transporter 1</name>
        <general-function>Reduced folate carrier activity</general-function>
        <specific-function>Transporter for the intake of folate. Uptake of folate in human placental choriocarcinoma cells occurs by a novel mechanism called potocytosis which functionally couples three components, namely the folate receptor, the folate transporter, and a V-type H(+)-pump.</specific-function>
        <gene-name>SLC19A1</gene-name>
        <locus/>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>24-44
71-89
96-116
124-144
160-177
187-203
260-287
310-327
334-354
361-378
395-419
434-454</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>64867.62</molecular-weight>
        <chromosome-location>21</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10937</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P41440</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S19A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>FLOT1</synonym>
          <synonym>FOLT</synonym>
          <synonym>IFC-1</synonym>
          <synonym>Intestinal folate carrier 1</synonym>
          <synonym>Placental folate transporter</synonym>
          <synonym>Reduced folate carrier protein</synonym>
          <synonym>RFC</synonym>
          <synonym>RFC1</synonym>
          <synonym>Solute carrier family 19 member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008562|Folate transporter 1
MVPSSPAVEKQVPVEPGPDPELRSWRHLVCYLCFYGFMAQIRPGESFITPYLLGPDKNFT
REQVTNEITPVLSYSYLAVLVPVFLLTDYLRYTPVLLLQGLSFVSVWLLLLLGHSVAHMQ
LMELFYSVTMAARIAYSSYIFSLVRPARYQRVAGYSRAAVLLGVFTSSVLGQLLVTVGRV
SFSTLNYISLAFLTFSVVLALFLKRPKRSLFFNRDDRGRCETSASELERMNPGPGGKLGH
ALRVACGDSVLARMLRELGDSLRRPQLRLWSLWWVFNSAGYYLVVYYVHILWNEVDPTTN
SARVYNGAADAASTLLGAITSFAAGFVKIRWARWSKLLIAGVTATQAGLVFLLAHTRHPS
SIWLCYAAFVLFRGSYQFLVPIATFQIASSLSKELCALVFGVNTFFATIVKTIITFIVSD
VRGLGLPVRKQFQLYSVYFLILSIIYFLGAMLDGLRHCQRGHHPRQPPAQGLRSAAEEKA
AQALSVQDKGLGGLQPAQSPPLSPEDSLGAVGPASLEQRQSDPYLAQAPAPQAAEFLSPV
TTPSPCTLCSAQASGPEAADETCPQLAVHPPGVSKLGLQCLPSDGVQNVNQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017517|Folate transporter 1 (SLC19A1)
ATGGTGCCCTCCAGCCCAGCGGTGGAGAAGCAGGTGCCCGTGGAACCTGGGCCTGACCCC
GAGCTCCGGTCCTGGCGGCACCTCGTGTGCTACCTTTGCTTCTACGGCTTCATGGCGCAG
ATACGGCCAGGGGAGAGCTTCATCACCCCCTACCTCCTGGGGCCCGACAAGAACTTCACG
CGGGAGCAGGTCACGAACGAGATCACGCCGGTGCTGTCGTACTCCTACCTGGCCGTGCTG
GTGCCCGTGTTCCTGCTCACCGACTACCTGCGCTACACGCCGGTGCTGCTGCTGCAGGGG
CTCAGCTTCGTGTCGGTGTGGCTGCTGCTGCTGCTGGGCCACTCGGTGGCGCACATGCAG
CTCATGGAGCTCTTCTACAGCGTCACCATGGCCGCGCGCATCGCCTATTCCTCCTACATC
TTCTCTCTCGTGCGGCCCGCGCGCTACCAGCGTGTGGCCGGCTACTCGCGCGCTGCGGTG
CTGCTGGGCGTGTTCACCAGCTCCGTGCTGGGCCAGCTGCTGGTCACTGTGGGCCGAGTC
TCCTTCTCCACGCTCAACTACATCTCGCTGGCCTTCCTCACCTTCAGCGTGGTCCTCGCC
CTCTTCCTGAAGCGCCCCAAGCGCAGCCTCTTCTTCAACCGCGACGACCGGGGGCGGTGC
GAAACCTCGGCTTCGGAGCTGGAGCGCATGAATCCTGGCCCAGGCGGGAAGCTGGGACAC
GCCCTGCGGGTGGCCTGTGGGGACTCAGTGCTGGCGCGGATGCTGCGGGAGCTGGGGGAC
AGCCTGCGGCGGCCGCAGCTGCGCCTGTGGTCCCTCTGGTGGGTCTTCAACTCGGCCGGC
TACTACCTGGTGGTCTACTACGTGCACATCCTGTGGAACGAGGTGGACCCCACCACCAAC
AGTGCGCGGGTCTACAACGGCGCGGCAGATGCTGCCTCCACGCTGCTGGGCGCCATCACG
TCCTTCGCCGCGGGCTTCGTGAAGATCCGCTGGGCGCGCTGGTCCAAGCTGCTCATCGCG
GGCGTCACGGCCACGCAGGCGGGGCTGGTCTTCCTTCTGGCGCACACGCGCCACCCGAGC
AGCATCTGGCTGTGCTATGCGGCCTTCGTGCTGTTCCGCGGCTCCTACCAGTTCCTCGTG
CCCATCGCCACCTTTCAGATTGCATCTTCTCTGTCTAAAGAGCTCTGTGCCCTGGTCTTC
GGGGTCAACACGTTCTTTGCCACCATCGTCAAGACCATCATCACTTTCATTGTCTCGGAC
GTGCGGGGCCTGGGCCTCCCGGTCCGCAAGCAGAATGAAGAACTGCATGTGGCTTCTCTG
TCTCTGTGGAAAAGCCATCTCAGGTTGGCGGCAGACACATTGTCATCAGAGGGGAGCAGC
GGCTCTGGTCCTCGGAGCTGGTTCCTCTCTCCCACCCTAAGGGCAGCCCTCCATGGTCCT
GTCTGTCCTTCTGAAGTGTGTCCATCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01770</identifier>
            <name>Folate_carrier</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>folic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>folic acid transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>methotrexate transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>reduced folate carrier activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>folic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>folic acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>methotrexate transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>reduced folate transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>water-soluble vitamin metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
  </carriers>
  <transporters/>
</drug>